Indirect costs associated with skin infectious disease in children: a systematic review

dc.contributor.authorLizano Díez, Irene
dc.contributor.authorNaharro, Jesús
dc.contributor.authorZsolt, Ilonka
dc.date.accessioned2022-06-02T08:25:57Z
dc.date.available2022-06-02T08:25:57Z
dc.date.issued2021-12-01
dc.date.updated2022-06-02T08:25:57Z
dc.description.abstractBackground: There are limited data in the literature on the indirect costs associated with skin and soft tissue infections (SSTIs) in the pediatric population. This study aimed to conduct a systematic review of the indirect costs associated with SSTIs in children. Methods: The search was conducted in PubMed, SCOPUS, and Web of Science up to January 2020. Thirteen search strategies were designed combining MeSH terms and free terms. SSTIs were defined as bacterial or viral infections, dermatomycoses, and parasitic infestations. Only primary studies were included. All analyzed costs were converted to 2020 Euros. Results: Thirteen of the identified publications presented indirect costs of SSTIs in children and were conducted in Argentina, Australia, Brazil, Hungary, New Zealand, Poland, Spain, Taiwan, and the USA. Nine studies described indirect costs associated with infection of Varicella-zoster virus: lost workdays by outpatient caregivers ranged from 0.27 to 7.8, and up to 6.14 if caring for inpatients; total productivity losses ranged from 1.16 to 257.46 per patient. Three studies reported indirect costs associated with acute bacterial SSTIs (community-associated methicillinresistant Staphylococcus aureus) in children: total productivity losses ranged from 1,814.39 to 8,224.06 per patient, based on impetigo, cellulitis, and folliculitis. One study of parasitic infestations (Pediculus humanus capitis) reported total indirect costs per patient of 68.57 (formal care) plus 21.41 due to time lost by parents in purchasing treatment. Conclusions: The economic burden of SSTIs is highly relevant but underestimated due to the lack of studies reporting indirect costs. Further cost studies will allow a better understanding of the magnitude of the financial burden of the disease. Keywords: Skin infectious diseases, Cost of illness, Indirect costs, Child, SSTIs, Systematic review
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec720591
dc.identifier.issn1472-6963
dc.identifier.urihttps://hdl.handle.net/2445/186197
dc.language.isoeng
dc.publisherBioMed Central
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s12913-021-07189-3
dc.relation.ispartofBMC Health Services Research, 2021, vol. 21, num. 2021, p. 1325
dc.relation.urihttps://doi.org/10.1186/s12913-021-07189-3
dc.rightscc-by (c) Lizano Díez, Irene et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationMalalties de la pell
dc.subject.classificationInfants malalts
dc.subject.classificationCost de l'assistència sanitària
dc.subject.otherSkin diseases
dc.subject.otherSick children
dc.subject.otherCost of medical care
dc.titleIndirect costs associated with skin infectious disease in children: a systematic review
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
720591.pdf
Mida:
771.21 KB
Format:
Adobe Portable Document Format